Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

2.

Magnetic Resonance Imaging-Based Radiomic Profiles Predict Patient Prognosis in Newly Diagnosed Glioblastoma Before Therapy.

McGarry SD, Hurrell SL, Kaczmarowski AL, Cochran EJ, Connelly J, Rand SD, Schmainda KM, LaViolette PS.

Tomography. 2016 Sep;2(3):223-228.

3.

Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.

Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS.

AJNR Am J Neuroradiol. 2016 Dec;37(12):2201-2208.

PMID:
27492073
4.

ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.

Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Prah M, Schmainda KM, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak DP, Mankoff DA; ACRIN 6684 Trial Group..

Clin Cancer Res. 2016 Oct 15;22(20):5079-5086.

PMID:
27185374
5.

Location of brain tumor intersecting white matter tracts predicts patient prognosis.

Mickevicius NJ, Carle AB, Bluemel T, Santarriaga S, Schloemer F, Shumate D, Connelly J, Schmainda KM, LaViolette PS.

J Neurooncol. 2015 Nov;125(2):393-400. doi: 10.1007/s11060-015-1928-5.

PMID:
26376654
6.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.

Boxerman JL, Schmainda KM, Zhang Z, Barboriak DP.

Neuro Oncol. 2015 Nov;17(11):1538-9. doi: 10.1093/neuonc/nov163. No abstract available.

7.

Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma.

Prah MA, Stufflebeam SM, Paulson ES, Kalpathy-Cramer J, Gerstner ER, Batchelor TT, Barboriak DP, Rosen BR, Schmainda KM.

AJNR Am J Neuroradiol. 2015 Sep;36(9):1654-61. doi: 10.3174/ajnr.A4374.

8.

Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients.

Jafari-Khouzani K, Emblem KE, Kalpathy-Cramer J, Bjørnerud A, Vangel MG, Gerstner ER, Schmainda KM, Paynabar K, Wu O, Wen PY, Batchelor T, Rosen B, Stufflebeam SM.

Transl Oncol. 2015 Jun;8(3):137-46. doi: 10.1016/j.tranon.2015.03.002.

9.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL.

Neuro Oncol. 2015 Aug;17(8):1148-56. doi: 10.1093/neuonc/nou364.

10.

Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma.

LaViolette PS, Mickevicius NJ, Cochran EJ, Rand SD, Connelly J, Bovi JA, Malkin MG, Mueller WM, Schmainda KM.

Neuro Oncol. 2014 Dec;16(12):1599-606. doi: 10.1093/neuonc/nou142.

11.

Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics.

Heroux MS, Chesnik MA, Halligan BD, Al-Gizawiy M, Connelly JM, Mueller WM, Rand SD, Cochran EJ, LaViolette PS, Malkin MG, Schmainda KM, Mirza SP.

Physiol Genomics. 2014 Jul 1;46(13):467-81. doi: 10.1152/physiolgenomics.00034.2014.

12.

The effect of low b-values on the intravoxel incoherent motion derived pseudodiffusion parameter in liver.

Cohen AD, Schieke MC, Hohenwalter MD, Schmainda KM.

Magn Reson Med. 2015 Jan;73(1):306-11. doi: 10.1002/mrm.25109.

13.

Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, Malkin MG.

Neuro Oncol. 2014 Jun;16(6):880-8. doi: 10.1093/neuonc/not216.

14.

Effect of contrast leakage on the detection of abnormal brain tumor vasculature in high-grade glioma.

LaViolette PS, Daun MK, Paulson ES, Schmainda KM.

J Neurooncol. 2014 Feb;116(3):543-9. doi: 10.1007/s11060-013-1318-9.

15.

Diffusion-weighted MRI as a biomarker for treatment response in glioma.

Schmainda KM.

CNS Oncol. 2012 Nov;1(2):169-80. Review.

16.

Multiphasic modification of intrinsic functional connectivity of the rat brain during increasing levels of propofol.

Liu X, Pillay S, Li R, Vizuete JA, Pechman KR, Schmainda KM, Hudetz AG.

Neuroimage. 2013 Dec;83:581-92. doi: 10.1016/j.neuroimage.2013.07.003.

17.

The effect of pulse sequence parameters and contrast agent dose on percentage signal recovery in DSC-MRI: implications for clinical applications.

Boxerman JL, Paulson ES, Prah MA, Schmainda KM.

AJNR Am J Neuroradiol. 2013 Jul;34(7):1364-9. doi: 10.3174/ajnr.A3477.

18.

Effects of perfusion on diffusion changes in human brain tumors.

Cohen AD, LaViolette PS, Prah M, Connelly J, Malkin MG, Rand SD, Mueller WM, Schmainda KM.

J Magn Reson Imaging. 2013 Oct;38(4):868-75. doi: 10.1002/jmri.24042.

19.

Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.

LaViolette PS, Cohen AD, Prah MA, Rand SD, Connelly J, Malkin MG, Mueller WM, Schmainda KM.

Neuro Oncol. 2013 Apr;15(4):442-50. doi: 10.1093/neuonc/nos323.

20.

The Role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard.

Boxerman JL, Prah DE, Paulson ES, Machan JT, Bedekar D, Schmainda KM.

AJNR Am J Neuroradiol. 2012 Jun;33(6):1081-7. doi: 10.3174/ajnr.A2934.

Items per page

Supplemental Content

Loading ...
Support Center